A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Trial Profile

A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs CP 101 Crestovo (Primary)
  • Indications Clostridium-difficile-infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRISM 3
  • Sponsors Crestovo; Finch Research & Development
  • Most Recent Events

    • 10 Apr 2018 Planned number of patients changed from 240 to 200.
    • 10 Apr 2018 Planned End Date changed from 1 May 2019 to 1 Nov 2019.
    • 10 Apr 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top